GLP-1 Therapies and Hair Loss: A Comprehensive Review of Evidence

GLP-1 receptor agonists (GLP-1 RAs) have revolutionized the treatment of type 2 diabetes and obesity, offering significant benefits in glycemic control and weight reduction. However, as their use has become widespread, an increasing number of anecdotal reports and patient concerns regarding hair loss have emerged. This systematic review meticulously consolidates the current scientific evidence on the association between GLP-1 therapies and alopecia, aiming to provide robust guidance for patient counseling and clinical practice.

The systematic review identified a consistent, albeit variable, reporting of hair loss among patients receiving GLP-1 receptor agonists. Across the analyzed studies, the incidence of alopecia ranged from approximately 5% to 15%, with some trials indicating a 2-fold to 3-fold higher risk compared to placebo groups. A significant correlation was observed between the onset of hair loss and periods of rapid and substantial weight reduction, particularly when patients experienced a body weight loss exceeding 10% within the initial 3 to 6 months of therapy. > The most critical finding was that the majority of reported hair loss cases were consistent with telogen effluvium, a temporary form of hair shedding triggered by physiological stress, rather than permanent hair loss. While generally reversible, these episodes often caused considerable distress, highlighting the need for proactive patient education and management strategies.